Canada now has a GLP-1 pill approved specifically for weight loss, and it is not a peptide. Health Canada authorized Eli Lilly's Foundayo on Nov. 13, with the decision announced publicly this week and pills expected in pharmacies in January.
What Happened
Foundayo's active ingredient is orforglipron, a non-peptide small-molecule GLP-1 receptor agonist taken once daily. Because the molecule is small enough to survive digestion, it can be swallowed rather than injected, and it carries no restrictions on when it is taken relative to food or water.
The authorization covers adults with obesity, and adults who are overweight with at least one weight-related condition such as high blood pressure or sleep apnea. Health Canada also cleared the drug to treat type 2 diabetes.
In the 72-week ATTAIN-1 trial, participants taking the highest dose who stayed on treatment lost a mean of 12.4% of body weight, against 0.9% on placebo. That is meaningful but well short of the 20%-plus weight loss reported for injectable tirzepatide and semaglutide at their top doses — the gap that still separates oral and injectable options.
Dr. Ehud Ur, a Vancouver endocrinologist unaffiliated with either manufacturer, told Canadian reporters the pill "seems to be just as good as if not better" for weight loss. He also said his prescribing would depend on the patient, partly because cardiovascular-outcome data for orforglipron is still pending — semaglutide and tirzepatide already carry proven cardiovascular benefit.
Who Is Affected
Statistics Canada figures put obesity at roughly one in three Canadian adults, and until now the only oral GLP-1 available in the country was Rybelsus, approved for type 2 diabetes only.
Compounding pharmacies and telehealth sellers that built businesses on injectable semaglutide face a different pressure: an approved oral alternative that requires no vial, no syringe and no sterile handling.
The group most immediately affected may be patients who declined injections. Clinicians have consistently reported that needle aversion is a real barrier, and a daily tablet removes it.
Timeline
- Nov. 13, 2026 — Health Canada issues the authorization.
- Nov. 18, 2026 — the decision becomes public; Lilly says supply is being staged.
- January 2027 — pills expected to reach Canadian pharmacies.
- Undated — Novo Nordisk's oral Wegovy, already approved in the United States, remains under review at Health Canada.
Oral Wegovy is a different technical solution: it is semaglutide, a large peptide, formulated with salcaprozate sodium, which temporarily reduces acidity around the tablet so the peptide can cross the stomach lining intact.
What This Means for Researchers
Orforglipron is the first approved GLP-1 that is not a peptide, which makes it a useful control in formulation and bioavailability work. It also resets expectations for the oral category: convenience is now a licensed claim, not a marketing one, and the remaining question is outcomes rather than absorption.
Pricing is unresolved. Lilly has not announced Canadian list pricing or public coverage, and the U.S. self-pay list price of $149 per month is not a guide to what Canadian patients will pay.
How to Verify Your Peptides
For injectable or research peptides, documentation still decides quality. Review the methods behind a certificate of analysis before trusting any purity figure:
Safe Alternatives
Compare compound background pages on our peptides directory and supplier profiles in the vendor directory before choosing a source.
Sources
Regulatory announcements (Health Canada authorization, Nov. 13, 2026); industry reports and clinician interviews carried by Canadian news outlets; manufacturer clinical trial disclosures.